Filter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
September 23, 2025 - … arrangements; the potential of our commercial business and pipeline programs, including nusinersen; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … arrangements; the potential of our commercial business and pipeline programs, including nusinersen; and risks and …
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
September 18, 2025 - … Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates Biogen to Acquire Alcyone Therapeutics, … Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates September 18, 2025 News Release General … approval of ThecaFlex DRx™ with nusinersen and additional pipeline products, securing all rights to ThecaFlex DRx™. It …
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
September 17, 2025 - … arrangements; the potential of our commercial business and pipeline programs, including ZURZUVAE; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … arrangements; the potential of our commercial business and pipeline programs, including ZURZUVAE; and risks and …
Biogen Thematic Pipeline Seminar: Lupus Presentation
Wed, 09/03/2025 - 10:00 - … Biogen Thematic Pipeline Seminar: Lupus Biogen Thematic Pipeline Seminar: Lupus Event Type Conference Presentation … Listen to webcast Supporting Materials Biogen Thematic Pipeline Seminar: Lupus 2.5 MB Sep 3, 2025 10:00 AM EDT … Biogen Thematic Pipeline Seminar: Lupus …
Biogen Highlights Multiple Assets and Indications in Lupus
September 3, 2025 - … first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated … with UCB; the innovation of our lupus and other pipeline products; Biogen’s plan to build on its leading … to expand into the lupus market; the potential of Biogen’s pipeline in early-stage development, including felzartamab in …
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
September 2, 2025 - … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and …
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
September 2, 2025 - … the potential of Biogen's commercial business and pipeline programs, including zorevunersen; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … the potential of Biogen's commercial business and pipeline programs, including zorevunersen; and risks and …
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
August 29, 2025 - … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and …
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
August 25, 2025 - … the potential of Biogen's commercial business and pipeline programs, including zorevunersen; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … the potential of Biogen's commercial business and pipeline programs, including zorevunersen; and risks and …
